PPQ in the FDA process validation lifecycle (Stage 2)

Process performance qualification is the second half of Stage 2 in the FDA's 2011 guidance Process Validation: General Principles and Practices, the point at which development knowledge is tested against commercial reality. Stage 1, Process Design, establishes the process and its control strategy. Stage 2, Process Qualification, covers facility, utility and equipment qualification, then PPQ itself. Stage 3, Continued Process Verification, maintains the validated state in routine manufacturing.

The guidance replaced the older idea of "three validation batches" with a lifecycle in which evidence accumulates before and after the PPQ campaign. It also expects commercial distribution to wait until PPQ is complete, with concurrent release allowed only in defined, justified circumstances.

The EU framework reaches the same place by a different route. EU GMP Annex 15, Qualification and Validation (in operation since 1 October 2015), describes traditional, continuous and hybrid approaches to process validation, requires acceptance criteria to be set before the batches are run, and expects the batch number to be justified by quality risk management.

Prerequisites: qualified facility and equipment, validated methods, completed characterization

A process performance qualification campaign can begin only when four prerequisites are closed, and campaigns fail most often because one was treated as parallel work rather than a gate. Each should have an approved report before the first PPQ batch starts.

• Facility, utility and equipment qualification. Installation, operational and performance qualification for cleanrooms, HVAC, water for injection, clean steam, bioreactors, chromatography skids, filtration and the control system.
• Validated analytical methods. Every release, in-process and characterization method in the protocol validated for specificity, range, accuracy, precision and, where relevant, LOD and LOQ, and transferred to the laboratory that will test PPQ samples.
• Completed process characterization. Critical process parameters, proven acceptable ranges and the control strategy approved, because they define what PPQ monitors and what counts as success.
• Supporting validation. Cleaning validation, hold-time studies, mixing studies, filter validation, resin and membrane lifetime protocols and shipping validation completed or scheduled alongside the campaign.

An engineering batch at commercial scale is not formally required but is standard practice; it finds procedural errors at a fraction of the cost of a failed PPQ batch.

Protocol elements and acceptance criteria

The protocol is the scientific definition of the process performance qualification, and every element the FDA guidance lists should be present and approved by the quality unit before execution.

Two choices cause most later disputes: whether in-process acceptance criteria sit at the release specification or at tighter limits derived from characterization, and how a batch is judged when one enhanced-sampling result misses its protocol limit but release results pass. Both belong in the protocol, not in the report.

How many PPQ batches: justify, do not default to three

Neither the FDA guidance nor Annex 15 fixes the number of process performance qualification batches, and both require it to be justified. Annex 15 states that a minimum of three consecutive batches under routine conditions could constitute a validation of the process, while requiring each manufacturer to justify its own number. The FDA guidance ties the number to the manufacturer's confidence in the process, based on development knowledge and prior experience.

The justification should rest on identifiable factors: variability seen in clinical and engineering batches, process complexity and novelty, platform precedent, the statistical approach to inter-batch consistency, and the degree of enhanced sampling. Three batches remain common for antibodies on well-understood platforms. Novel formats, high-variability steps, or a need for narrow capability estimates often justify four or five. A protocol can also set a minimum number with pre-set triggers for additional batches if variability exceeds expectations.

Enhanced sampling beyond routine release

Enhanced sampling distinguishes a process performance qualification batch from a routine batch, and the FDA guidance is explicit that PPQ will in most cases involve more sampling, additional testing and greater scrutiny than routine production. The purpose is to characterize intra- and inter-batch variability well enough to justify the Stage 3 monitoring plan.

For a mammalian drug substance process, enhanced sampling typically adds:

• Daily bioreactor samples for cell density, viability and metabolites, plus product-quality attributes such as glycan profile and charge variants at defined days.
• Impurity clearance at every purification step: host cell protein, host cell DNA, residual Protein A and aggregates on each column pool, not only on final drug substance.
• Bioburden and endotoxin at every intermediate hold, with at least one batch run to the maximum validated hold time.
• Column yield, pool volume, transition analysis and pressure profile for each cycle.
• Bulk homogeneity sampling from top, middle and bottom of the final container, plus extra containers on stability.

Each added sample needs a validated method and either an acceptance criterion or a "report result" designation decided in advance; data without a pre-set criterion invite questions at inspection.

The PPQ report and its place in BLA Module 3

The process performance qualification report converts batch data into a validated process, and it is what the reviewer and the pre-license inspector read. The FDA guidance expects it to cross-reference every protocol element, summarize and analyze the data, evaluate unexpected observations, describe corrective actions, and state a clear conclusion with quality unit approval.

In the Common Technical Document, the drug substance PPQ summary is filed in Module 3 section 3.2.S.2.5, Process Validation and/or Evaluation, with the control strategy in 3.2.S.2.4 and development history in 3.2.S.2.6. Viral clearance validation is filed in 3.2.A.2, Adventitious Agents Safety Evaluation; drug product PPQ follows 3.2.P.3.5. The dossier carries a summary with batch results tabulated against acceptance criteria; the full report stays at the site for inspection.

Timing is tight. PPQ batches must be complete, with initial stability data, before a BLA is submitted, and the pre-license inspection will walk the PPQ batch records.

What a CDMO's PPQ service covers

PPQ services from a CDMO should cover the process performance qualification campaign from protocol drafting to report approval, and a sponsor comparing PPQ services should check for each item below rather than for the phrase "process validation" alone.

• Facility, utility and equipment qualification reports available for sponsor review and inspection.
• Validated and transferred analytical methods for every protocol test, with method validation reports.
• Protocol authorship with sponsor approval, including the statistical plan and the batch-number justification.
• Enhanced sampling execution and sample management, including stability placement.
• Deviation and out-of-specification investigation under the site quality system, with sponsor notification terms in the quality agreement.
• Supporting validation: cleaning, hold times, resin and membrane lifetime, filter validation, shipping.
• PPQ report authorship, Module 3 section drafts and pre-license inspection support.
• A defined transition into Stage 3, with the continued process verification plan agreed before the campaign ends.

The quality agreement should state who approves the protocol, who owns deviations and how a failed batch is handled commercially, because once the campaign is running these decisions are made under time pressure.